JP2009528985A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528985A5
JP2009528985A5 JP2008552918A JP2008552918A JP2009528985A5 JP 2009528985 A5 JP2009528985 A5 JP 2009528985A5 JP 2008552918 A JP2008552918 A JP 2008552918A JP 2008552918 A JP2008552918 A JP 2008552918A JP 2009528985 A5 JP2009528985 A5 JP 2009528985A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
trkb
agonist
trkb agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008552918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/000254 external-priority patent/WO2007088476A1/en
Publication of JP2009528985A publication Critical patent/JP2009528985A/ja
Publication of JP2009528985A5 publication Critical patent/JP2009528985A5/ja
Withdrawn legal-status Critical Current

Links

JP2008552918A 2006-02-02 2007-02-01 ｔｒｋＢアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法 Withdrawn JP2009528985A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76541006P 2006-02-02 2006-02-02
PCT/IB2007/000254 WO2007088476A1 (en) 2006-02-02 2007-02-01 Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist

Publications (2)

Publication Number Publication Date
JP2009528985A JP2009528985A (ja) 2009-08-13
JP2009528985A5 true JP2009528985A5 (enExample) 2009-10-15

Family

ID=38093467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552918A Withdrawn JP2009528985A (ja) 2006-02-02 2007-02-01 ｔｒｋＢアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法

Country Status (17)

Country Link
US (2) US20070248611A1 (enExample)
EP (1) EP1988923A1 (enExample)
JP (1) JP2009528985A (enExample)
KR (1) KR20080091838A (enExample)
CN (1) CN101400367A (enExample)
AR (1) AR059304A1 (enExample)
AU (1) AU2007210862A1 (enExample)
BR (1) BRPI0707482A2 (enExample)
CA (1) CA2637826A1 (enExample)
DO (1) DOP2007000021A (enExample)
IL (1) IL193069A0 (enExample)
NL (1) NL2000464C2 (enExample)
PE (1) PE20071364A1 (enExample)
RU (1) RU2008131939A (enExample)
TW (1) TW200808352A (enExample)
UY (1) UY30128A1 (enExample)
WO (1) WO2007088476A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
AU2007316418A1 (en) * 2006-11-09 2008-05-15 Irm Llc Agonist TrkB antibodies and uses thereof
US20100086997A1 (en) * 2006-12-20 2010-04-08 Rinat Enuroscience Corp TrkB Agonists for Treating Autoimmune Disorders
JP2011501760A (ja) * 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
GB2491106A (en) * 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
MX2020003550A (es) * 2017-11-30 2020-08-03 Regeneron Pharma Anticuerpos monoclonales anti-trkb y metodos de uso.

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5364768A (en) * 1987-07-07 1994-11-15 Farmitalia Carlo Erba S.R.L. Process for the preparation of penems
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
ATE219519T1 (de) * 1989-01-23 2002-07-15 Chiron Corp Rekombinanttherapien für infektionen und hyperproliferative störungen
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
US5644034A (en) * 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US6566091B1 (en) * 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US6506728B2 (en) * 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
CA2055812A1 (en) * 1990-11-20 1992-05-21 Carl N. Skold Method of stabilizing enzyme conjugates
US20030134815A1 (en) * 1991-08-20 2003-07-17 The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2143739A1 (en) * 1992-09-07 1994-03-17 Andrew T. Holder Growth hormone potentiating molecules
AU4920893A (en) * 1992-09-14 1994-04-12 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
AU6818094A (en) * 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
JP2534968B2 (ja) * 1993-05-27 1996-09-18 チッソ株式会社 フラビン還元酵素遺伝子
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
AU2589095A (en) * 1994-05-16 1995-12-05 Washington University Cell membrane fusion composition and method
DE59510779D1 (de) * 1994-06-24 2003-10-02 Dade Behring Marburg Gmbh Verfahren zur Stabilisierung von hydrolyseempfindlichen Molekülen
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
JP4671372B2 (ja) 1996-11-15 2011-04-13 ジェネンテック， インコーポレイテッド ニューロトロフィンの精製
AU718500B2 (en) * 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
PL195273B1 (pl) * 1997-08-29 2007-08-31 Vertex Pharma Związki wykazujące aktywność neuronalną, kompozycja farmaceutyczna zawierająca taki związek oraz zastosowanie tych związków
AU9692198A (en) * 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
AU6205700A (en) * 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated Azo amino acid derivatives for the treatment of neurological diseases
AU5914200A (en) * 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated Amino-alkyl derivatives
EP1200440A1 (en) * 1999-07-06 2002-05-02 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
JP2003503482A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミノ酸誘導体
EP1226139A2 (en) * 1999-07-06 2002-07-31 Vertex Pharmaceuticals Incorporated Cyclized amide derivatives for treating or preventing neuronal damage
JP2003505508A (ja) * 1999-07-30 2003-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非環式又は環式アミド誘導体
WO2001030375A2 (en) * 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
WO2001060398A1 (en) * 2000-02-18 2001-08-23 Sumitomo Pharmaceuticals Company, Limited Drugs for ameliorating impaired glucose tolerance
WO2001066133A1 (fr) * 2000-03-06 2001-09-13 Sumitomo Pharmaceuticals Company, Limited Agents d'amelioration de la resistance a la leptine
MXPA02012602A (es) 2000-06-22 2003-05-14 Genentech Inc Anticuerpos monoclonales agonistas anti-trk-c.
US7060429B2 (en) * 2001-02-22 2006-06-13 University Of Maryland, Baltimore Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
WO2002102381A1 (en) * 2001-06-14 2002-12-27 Vertex Pharmaceuticals Incorporated Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BRPI0506793A (pt) 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Similar Documents

Publication Publication Date Title
JP2009528985A5 (enExample)
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
JP2009522296A5 (enExample)
JP2016539156A5 (enExample)
IL197420A (en) Polymorphic form of 4 - [3 - (4 - cyclopropanecarbonyl - piperazine - 1 - carbonyl) - 4 - fluoro - benzyl] - h2 - phthalazine - 1 - on, methods of preparation, a pharmaceutical preparation containing it and uses in this form to prepare drugs for the treatment of the human body
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
EP2583978A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
Lee et al. Comparison of ramosetron plus dexamethasone with ramosetron alone on postoperative nausea, vomiting, shivering and pain after thyroid surgery
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
HRP20140745T1 (hr) Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja
HRP20151230T1 (hr) Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
JP2009280621A5 (enExample)
JP2010222367A5 (enExample)
JP2007504174A5 (enExample)
RU2008131939A (ru) Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
WO2007123865A3 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
JP2007523135A5 (enExample)
WO2015070234A3 (en) Neuroprotective compounds and use thereof
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
CL2007002196A1 (es) Compuestos heterociclicos nitrogenados, moduladores de la actividad del receptor de quimioquina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, obesidad, sindrome metabolico y dolor.
JP2012528856A5 (enExample)
JP2007119497A5 (enExample)
JP2011500589A5 (enExample)